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Background. Human norovirus is a significant public health burden, with >30 genotypes causing endemic levels of disease 
and strains from the GII.4 genotype causing serial pandemics as the virus evolves new ligand binding and antigenicity features. 
During 2014–2015, genotype GII.17 cluster IIIb strains emerged as the leading cause of norovirus infection in select global locations. 
Comparison of capsid sequences indicates that GII.17 is evolving at previously defined GII.4 antibody epitopes.
Methods. Antigenicity of virus-like particles (VLPs) representative of clusters I, II, and IIIb GII.17 strains were compared by a 
surrogate neutralization assay based on antibody blockade of ligand binding.
Results. Sera from mice immunized with a single GII.17 VLP identified antigenic shifts between each cluster of GII.17 strains. 
Ligand binding of GII.17 cluster IIIb VLP was blocked only by antisera from mice immunized with cluster IIIb VLPs. Exchange of 
residues 393–396 from GII.17.2015 into GII.17.1978 ablated ligand binding and altered antigenicity, defining an important varying 
epitope in GII.17.
Conclusions. The capsid sequence changes in GII.17 strains result in loss of blockade antibody binding, indicating that viral evo-
lution, specifically at residues 393–396, may have contributed to the emergence of cluster IIIb strains and the persistence of GII.17 
in human populations.
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Human noroviruses are the leading cause of acute viral gastro-
enteritis [1–3], justifying substantial investment in understanding 
the mechanisms of molecular evolution, determining the epide-
miology and persistence of these viruses in populations, and vac-
cine development [1–5]. Extensive genetic diversity (there are >30 
known genotypes) and antigenic drift within the predominant 
genotype (GII.4) make determining which strains to target in a 
multivalent virus-like particle (VLP) vaccine platform a primary 
challenge. For the past 2 decades, GII.4 strains have accounted for 
70%–80% of norovirus outbreaks, providing a key target for the 
vaccine [6]. Recently, in parts of Asia, GII.17 strains have replaced 
GII.4.2012 strains as the predominant cause of norovirus out-
breaks [7]. Phylogenetic analyses of these emergent strains suggest 
that they are evolving via an epochal pattern of evolution, perhaps 
in response to herd immunity, similarly to the GII.4 strains [7–9].
Norovirus Hu/GII.17/C142/1978/GUF (GII.17.1978) is the 
first GII.17 strain reported in GenBank and defines cluster I of 
the genotype. Strains remained genetically static until 2005, 
when the cluster II strains emerged [10]. Despite significant 
capsid sequence changes between clusters I  and II, GII.17 
strains were rarely detected in outbreak investigations [7]. The 
cluster III strains subsequently diverged into subclusters IIIa 
and IIIb, based on the sequence of the major capsid protein 
[11, 12]. In the winter season of 2014–2015, cluster IIIb strains 
became the predominant cause of norovirus outbreaks in China 
[8]. The IIIb strains spread, causing epidemic levels of disease in 
parts of Southeast Asia but only sporadic infections in Europe, 
Australia, and North America [7].
Compared with cluster I and II strains, cluster III strains have 
a unique RNA-dependent RNA polymerase (RDRP; GII.P17) and 
both insertions and deletions in the capsid gene, particularly in the 
P2 subdomain, that could affect both ligand binding and antige-
nicity profiles [7, 12, 13]. P particles of a reported cluster III strain 
bind to the saliva of blood-type O, A, and B individuals, and secre-
tor-positive persons of all blood types experienced symptomatic 
infection during an outbreak, indicating broad histo-blood group 
antigen binding by this strain. Antigenicity differences between 
the clusters, determined using GII.17-derived antisera, have only 
been evaluated by a single convalescent serum sample, which 
preferentially blocked binding of the homotypic cluster III strain, 
compared with heterologous strain P particles [14].
Here, we empirically evaluated whether genetic differences 
in the major capsid gene between GII.17 clusters translated 
into antigenic changes by comparing the blockade antibody 
(Ab) response to a panel of VLPs representing cluster I, II, 
and IIIb strains, using polyclonal sera from adult humans 
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and immunized mice. While blockade Ab titers in human 
sera were similar between the different GII.17 clusters, sera 
from mice immunized with a single GII.17 strain from each 
cluster demonstrated clear antigenic differences between the 
GII.17 strains, particularly the emergent cluster IIIb strain, 
GII.17.2015. These data confirm that the capsid sequence of 
the GII.17 genocluster is evolving at Ab epitopes, potentially 
allowing for escape from herd immunity and widespread dis-
ease. These findings demonstrate that norovirus GII genotypes 
other than GII.4 are capable of epochal evolution and anti-
genic drift, enhancing their pandemic potential. Our data sup-
port the hypothesis that enhanced strain-specific surveillance 
and vaccine efficacy trials, similar to those in place for GII.4 
norovirus strains, are warranted against these newly defined, 
rapidly evolving GII.17 strains.
MATERIALS AND METHODS
Ethics Statement
Healthy human adult volunteers provided samples in June 2016, 
according to established institutional review board guidelines, 
after providing informed consent. Peripheral blood specimens 
were collected by venipuncture without anticoagulant and 
allowed to clot. Serum was removed, aliquoted, and stored at 
−80°C. Before use, sera underwent heat inactivation for 30 min-
utes at 56°C. Experimentation guidelines of the US Department 
of Health and Human Services were followed.
Ethics Statement on Mouse Studies
Mouse studies were executed in accordance with the rec-
ommendations for the care and use of animals by the Office 
of Laboratory Animal Welfare at the National Institutes of 
Health. The Institutional Animal Care and Use Committee at 
the University of North Carolina–Chapel Hill approved the 
animal studies performed here (protocol 14–090). Eight-week-
old Balb/c mice (Charles River Laboratories) were immunized 
intramuscularly with 0.2  µg of VLPs adjuvanted with 5  µg of 
monophosphoryl lipid A and 50 µg of alhydrogel, mimicking 
the human norovirus vaccine [15]. Booster vaccinations were 
performed on days 28 and 62. Mice were euthanized with iso-
flurane on day 69, and terminal blood specimens were collected.
Modeling of GII.17 Amino Acid Changes Over Time
For this study, 4 GII.17 P2 subdomain capsid sequences were 
compared and analyzed, including GII.17.1978 (KC597139, 
cluster I), GII.17.2002 (KJ196286, cluster I), GII.17.2005 
(DQ438972, cluster II), and GII.17.2015 (KP698930, cluster 
IIIb). For visual purposes, residue changes between the strains 
were highlighted onto the homology model of GII.17.2002 in 
Figure 1 [13]. The individual P2 subdomain monomer models 
were converted into dimers in Pymol, and the structural mod-
els were analyzed and colored to highlight epitopes and amino 
acid changes that occurred over time. For Figure 2, homology 
models of these 4 sequences were generated using the SWISS-
MODEL server (available at: https://swissmodel.expasy.org/
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Figure 1. GII.17 capsid P2 domain residue changes over time. A, Structural model of GII.17.2002 P domain dimer (shades of gray) with GII.4 surface-exposed blockade 
epitope A (yellow), D (blue), and E (magenta) highlighted. B–D, Residue changes between 1978 and 2002 (red; B), between 2002 (cluster I) and 2005 (cluster II; cyan; C), and 
between 2005 (cluster II) and 2015 (cluster IIIb; orange; D).
interactive) with default settings. Briefly, the entire capsid 
sequence was uploaded into the server in Fasta format, and 
the “Select Templates” option was selected. For each of the 4 
sequences, the template with the highest identity was chosen. 
For GII.17.1987, GII.17.2002, and GII.17.2005, the template 
identified was Protein Data Bank accession number 5F4J [13], 
which is the crystal structure for the GII.17.2002 virus capsid. 
For GII.17.2015, the template identified was Protein Data Bank 
accession number 5LKC [16], which is the crystal structure 
for the GII.17.2015 capsid. Homology models were built using 
these templates and exported in pdb format for rendering in 
MacPymol, version 1.8.0.4 (available at: https://www.pymol.
org/). Electrostatic potential was predicted using the vacuum 
electrostatics function in MacPymol, which warned that the 
results were only qualitatively useful. The amino acid sequences 
were aligned and compared using Clustal X, version 2.1 [17].
GII.17 VLPs
Capsid sequences were synthesized by Bio–Basic (Amherst, 
NY), and VLPs (Table 1) were expressed in baby hamster kid-
ney cells from Venezuelan equine encephalitis virus replicons 
expressing GII.17 open reading frame 2 protein, as described 
previously [18]. Particle integrity was confirmed by visualiza-
tion of approximately 40-nm particles, using electron micros-
copy. VLP binding to pig gastric mucin (PGM) type III (Sigma 
Aldrich, St. Louis, MO) and human type B saliva was detected 
by polyclonal antiserum to GII.17 strains (Cocalico Biologicals, 
Stevens, PA), as described elsewhere [19, 20]. Half-maximum 
binding was defined in comparison to a VLP concentration of 
4 µg/mL.
IgG Enzyme Immunoassay (EIA) and Blockade Ab
EIA and blockade Ab assays were performed at 37°C. VLPs were 
used at concentrations of 0.25 µg/mL for EIA and 0.5 µg/mL for 
blockade assays [19, 21]. Mean half-maximum effective concen-
trations (EC50 values) and 95% confidence intervals (CIs) were 
determined from dose-response sigmoidal curve fits, using 
GraphPad 6.02 [22, 23]. To be positive by EIA, a sample had to 
have a minimum OD450 of >3 times the background level after 
background subtraction. Samples determined to be below this 
limit by EIA (half-maximum binding was defined in compari-





Figure 2. Surface-exposed charge changes over time. The electrostatic potential (blue, positive; red, negative) of the top surface of the P2 subdomain is shown for 
GII.17.1978 (A), GII.17.2002 (B), GII.17.2005 (C), and GII.17.2015 (D). Surface-exposed charge changes in 2015 likely drove antigenic changes, particularly a 4 aspartic acid 
motif at positions 393–396 (circled).
least 50% of VLP binding to PGM at the lowest serum dilution 
tested were assigned a titer equal to 0.5 times the limit of detec-
tion, for statistical analysis.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.02 
[22, 24]. EC50 values were log transformed and compared by 
the Dunn multiple comparisons test (performed after analysis 
of variance) [24]. A difference was considered significant if it 
had a P value of <.05.
RESULTS
Representative strains of GII.17 clusters I (1978, 2002), II (2005), 
and IIIb (2015) were selected for analysis of antigenic properties 
(Table 1). Amino acid sequence alignment of the strains sug-
gested that each cluster likely has unique antigenic properties 
based on residue changes in known GII.4 blockade Ab epitopes 
(Figure 1). However, these residues have not been established 
to comprise Ab epitopes in any strains other than GII.4. In 
addition, vacuum electrostatics was used to predict the sur-
face-exposed charge of each of the 3 clusters over time (Figure 
2). Charge rearrangements occurred between each of the 3 clus-
ters. Cluster IIIb exhibited a major charge change with extensive 
negative potential in an area that was not strongly positive or 
negative in previous clusters, indicating a potential antigenic 
change. This single motif, spanning positions 393–396 and 
comprising 4 aspartic acids, is unique to this cluster. Notably, 
this region corresponds to a known carbohydrate-binding site 
in GII.4 noroviruses [24, 25].
To test whether these charge changes correlate with anti-
genic changes, an Ab blockade of VLP binding to ligand assay 
was developed for the GII.17 VLPs. Each GII.17 VLP bound 
to PGM, although cluster I  VLPs (1978 and 2002)  required 
more VLPs to reach half-maximum binding than cluster II and 
IIIb VLPs (Table  1). First, human donor sera were measured 
for potential neutralization activity against each GII.17 cluster 
VLP and an additional VLP with wide population exposure, 
GII.4.2012 (Figure 3). Of 16 sera, 12 (75%) blocked GII.4.2012 
(geometric mean titer [GMT], 32.8; 95% confidence interval 
[CI], 14.5–74.2), 6 (38%) blocked GII.17.1978 (GMT, 13.4; 95% 
CI, 6.1–29.7), 5 (31%) blocked GII.17.2005 (GMT, 11.0; 95% 
CI, 5.3–22.8), and 8 (50%) blocked GII.17.2015 (GMT, 13.3; 
95% CI, 6.9–25.4). GMTs were similar between GII.17 strains 
and GII.4.2012, indicating preexposure history in this group 
of adults. GMTs were also similar between the GII.17 strains, 
indicating that GII.17 strains share common blockade Ab epi-
topes either with each other or with other prevalent GII strains 
or that the population has been exposed to the panel of strains 
over time.
To determine whether the GII.17 strains share blockade epi-
topes, mice were immunized with either GII.17.1978, 2002, 
2005, or 2015 VLPs, and serum reactivity was compared across 
the VLP panel by IgG EIA and blockade Ab. In support of 
human sera blockade Ab cross-reactivity findings, we observed 
that sera from mice immunized with a single GII.17 strain VLP 
reacted similarly across the GII.17 clusters, as revealed by IgG 
EIA (data not shown), indicating a degree of conserved inter-
cluster Ab epitopes. To measure the potential for cross-strain 
protection as the virus evolves, we analyzed each serum sam-
ple for blockade activity across the 3 GII.17 clusters (Figure 4). 
GII.17.1978 VLP was blocked similarly by sera from 1978 
(GMT, 1544; 95% CI, 788.9–3021), 2002 (GMT, 1886; 95% CI, 
622.2–5718), and 2015 (GMT, 96.78; 95% CI, 43.73–214.2) and 
less well by GII.17.2005 sera (GMT, below the limit of detec-
tion). Although titer differences were not significant, 2015 
sera GMTs were 16-fold less than 1978 GMTs. GII.17.2005 
VLP was blocked similarly by homotypic (GMT, 2378; 95% 
CI, 1527–3701) and GII.17.2002 (GMT, 187.3; 95% CI, 28.33–
1239) sera and less well by GII.17.1978 (GMT, 77.97; 95% CI, 
22.71–267.7) and 2015 (GMT, 67.02; 95% CI, 29.71–151.1) 
sera, supporting the trend of reduced cross-cluster serum 


























Figure 3. Adults have similar blockade antibody (Ab) titers to a time-ordered panel 
of GII.17 strains. Serum collected for donation from 16 adults (colored markers) living 
in the United States was evaluated for blockade Ab titer to GII.4.2012 and time-or-
dered GII.17 virus-like particles from clusters I (1978), II (2005), and IIIb (2015). Bars 
denote geometric mean titers, and whiskers denote 95% confidence intervals. EC50, 
half-maximum effective concentration. Dashed line equals the limit of detection.








EC50 PGM Binding, 
µg/mL, Mean  
(95% CI)
GII.17.1978 KC597139 Cluster I 1.23 (1.15–1.34)b
GII.17.2002 KJ196286 Cluster I 1.43 (1.29–1.58)b
GII.17.2005 DQ438972 Cluster II 0.58 (0.51–0.66)




Abbreviations: CI, confidence interval; EC50, half-maximum effective concentration; ORF2, 
open reading frame 2; PGM, pig gastric mucin.
aBased on work by Dang Thanh et al [33].
bSignificantly different from GII.17.2015, by analysis of variance.
reactivity [26]. Most notably, only sera from mice immunized 
with GII.17.2015 (GMT, 1265; 95% CI, 951.1–1684) were able 
to block GII.17.2015 VLP binding to PGM (Figure  4). None 
of the serum samples from mice immunized with cluster I or 
II VLPs blocked the cluster IIIb VLP binding to ligand. These 
data demonstrate progressive antigenic change culminating in 
the cluster IIIb GII.17 strains, which are antigenically distinct 
from clusters I and II strains that circulated prior to cluster IIIb 
emergence.
Cross-reactivity of blockade Ab responses between clusters 
agreed with electrostatic potential comparisons, indicating 
more antigenic similarity between clusters I and II and less 
similarity with cluster IIIb. Next, we tested whether residues 
393–396 of GII.17.2015 (Figure 2) may be contributing to the 
antigenic divergence of GII.17.2015, by developing a chimeric 
VLP composed of the GII.17.1978 sequence with the corre-
sponding residues replaced with the 4 aspartic acid residues 
found at positions 393–396 of GII.17.2015. The chimeric VLP, 
GII.17.1978–2015.393-396, formed approximately 40-nm par-
ticles, according to negative-stain electron microscopy (Figure 
5A). Polyclonal sera from an immunized rabbit and guinea 
pig had strong but reduced reactivity to the chimeric particles 
(Figure 5B). GII.17-type–specific monoclonal antibodies are 
necessary to distinguish the exact epitope variation encoded 
within the time-ordered GII.17 strain VLP panel. As these 
antibodies are not available, we compared reactivity patterns 
between GII.17.1978, 2015, and the chimeric VLP with mono-
clonal antibodies known to recognize conserved genogroup 
II epitopes. Human monoclonal Ab NVB 61.3 recognizes a 
conformation dependent epitope [24] and reacted strongly 
with each GII.17 VLP tested but had reduced reactivity to the 
GII.17.1978–2015.393-396 chimeric VLP. Mouse monoclonal 
Ab GII.4.2002.G3 [27] reacted less potently with GII.17.1978 
and 2015 and lost reactivity with GII.17.1978–2015.393-
396 (Figure 5C). Both polyclonal and monoclonal antibod-
ies differentiated the chimeric VLP from the parental VLPs. 
Exchange of 393–396 had a robust effect on VLP binding to 
ligand. The chimeric VLP had reduced binding to both PGM 
and human type B saliva as compared to the parental VLPs. At 
the titer used for Ab blockade assays, GII.17.1978–2015.393-
396 chimeric VLP binding was not detected above back-
ground binding for PGM or type B saliva (Figure 5D). These 
data suggest that the exchange of the 4 aspartic acid residues 
of GII.17.2015 with the corresponding residues in GII.17.1978 
either disrupted residues that affect both antigenicity and 
ligand binding of GII.17 strains or compromised particle 
integrity. Visual confirmation of particle size by microscopy 
and reactivity to conformation-dependent human monoclo-
nal Ab NVB 61.3 indicate that the chimeric VLP was intact 
and that residues 393–396 regulated blockade Ab and ligand 
binding properties.
DISCUSSION
Genome sequencing and analyses are powerful tools for global 
surveillance of RNA viruses, including influenza virus and 
human norovirus, which evolve into new serotypes and effec-
tively abrogate protective herd immunity. Although predictive 
tools continue to improve, the translation of genome sequences 
into antigenicity characteristics will continue to be largely an 
empirical exercise as features of Ab and T-cell epitopes and the 
role these epitopes play in protection from infection are fur-
ther developed. The observed pattern of epochal evolution in 
the capsid gene of the GII.17 strains has led to speculation that 
the genotype has the same potential for pandemic spread, as 
has been documented for the GII.4 norovirus strains [14, 25]. 
However, none of the identified changing residues have been 
established to be Ab epitopes in GII.17 or any other norovirus 
strain except GII.4 [24, 28]; thus, immunological assays are 
required for determining the effects of sequence change on anti-
genicity. This study is the first to empirically test the antigenic 
relationship between GII.17 strain VLPs and provide direct evi-
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Figure 4. GII.17.2015 is antigenically distinct from earlier GII.17 strains at blockade antibody (Ab) epitopes. Balb/c mice were immunized intramuscularly with 0.2 µg of a 
single GII.17 virus-like particle (VLP) adjuvanted with monophosphoryl lipid A and alhydrogel and sera were evaluated for blockade Ab titer to VLPs from clusters I (1978), II 
(2005), and IIIb (2015). Bars denote geometric mean titers, and whiskers denote 95% confidence intervals. Dashed line equals the limit of detection. *Significantly different 
from homotypic serum (by analysis of variance). EC50, half-maximum inhibitory concentration.
driven by herd immunity, results in antigenic drift and novel 
emergent GII.17 strains.
To do this, we developed a panel of VLPs presenting GII.17 
clusters I, II, and IIIb to evaluate whether the genetic clusters 
translate into antigenic clusters. Human sera blockade Ab 
responses were similar across the panel of GII.17 VLPs, indicat-
ing that either the VLPs share blockade epitopes or strain-specific 
Ab responses have formed after repeat exposures to genogroup 
II strains. Alternatively, donors may have experienced a recent 
GII.17 infection resulting in short-term cross-blockade Ab 
responses, as has been characterized following norovirus vac-
cination [22]. Responses in single-strain–immunized mice 
demonstrated that limited cross-cluster blockade Ab is gener-
ated between clusters after a single GII.17 exposure, indicat-
ing that the cross-cluster blockade Ab response in human sera 
is more likely the result of multiple exposures, not conserved 
blockade Ab epitopes. However, these studies cannot differen-
tiate whether participants have been exposed to GII.17 strains 
from all 3 clusters or whether exposure to multiple GII.17 
strains or other GII strains results in blockade Ab to epitopes 
that are conserved between strains, as has been demonstrated 
following GII.4 norovirus and influenza vaccination [22, 29]. 
Development of either of these mechanisms would be unlikely 
in young children, leaving them susceptible to infection with an 
emergent GII.17 strain.
Ligand binding and polymerase activity differences may have 
contributed to the epidemiologic characteristics of GII.17.2015 
[7, 12–14]. At this time, it is not possible to determine the effect 
of polymerase changes on viral fitness or antigenicity, but pre-
liminary neutralization assays using a novel virus cultivation 
system support a correlation between blockade Ab titer and 
virus neutralization titer. Serum that blocked VLP-ligand bind-
ing also neutralized virus [30]. The observation that GII.17.2015 
VLP binding to PGM was uniquely resistant to serum Ab block-
ade from mice immunized with VLP from other GII.17 clusters 
indicates that antigenic divergence at key residues likely played 
a role in cluster IIIb strain emergence. Although blockade Ab 
levels were reduced, cluster I and II strains remained suscepti-
ble to cross-cluster Ab blockade, agreeing with modeling data 
indicating that the GII.17 strains remained relatively static over 
time until the cluster III strains emerged [10]. Similar to GII.4 
norovirus VLPs, cross-reactive blockade Ab is more potent for 
previously circulating strains than for future strains, compared 
with the immunizing VLP [26]. Bioinformatics analyses iden-
tified the most prominent changes on the surface of the cluster 












































































Hyperimmunized guinea pig/rabbit sera
Figure 5. Exchange of residues 393–396 from GII.17.2015 to GII.17.1978 decreases antibody reactivity and virus-like particle (VLP) binding to ligand while maintaining 
particle structure. A–C, Chimeric VLPs maintain particle integrity, as visualized by electron microscopy (A) but reduced reactivity to polyclonal sera from hyperimmunized 
guinea pig or rabbit (B) and monoclonal antibodies to conserved genogroup II epitopes (C). D, Ligand binding to both pig gastric mucin (PGM) and human type B saliva also was 
reduced as compared to parental VLPs. Dashed line equals the limit of detection. *Significantly different from the chimeric VLP (by analysis of variance). EC50, half-maximum 
effective concentration; IgG, immunoglobulin G.
negative patch on the surface at positions 393–396. Exchange 
of these residues with corresponding residues in GII.17.1978 
reduced Ab reactivity and PGM binding, suggesting that the 
observed charge changes disrupted functional domains. The 
primary limitation of this study is the lack of GII.17-specific 
monoclonal antibodies that could definitively identify epitopes 
that are strain specific, as has been demonstrated for GII.4 nor-
ovirus [24]. The identified epitope likely involves additional res-
idues outside of 393–396.
Changes in residues 393–396 also negatively affected ligand 
binding, supporting a role for the ligand affinity and antigenicity 
of these amino acids, as has been described for residues 393–395 
(epitope D) of GII.4 strains [24, 25]. Epitope D is both a blockade 
Ab epitope and a regulator of ligand binding. Although not part 
of the carbohydrate-binding pocket, epitope D residues modu-
late affinity for different histo-blood group antigens [25, 31, 32]. 
Bioinformatics studies have suggested that the carbohydrate bind-
ing patterns may have changed between the early GII.17 strains 
and the cluster IIIb strains [13, 14]. This study did not character-
ize the carbohydrate binding profiles of the different cluster VLPs 
by specific carbohydrates, but each cluster VLP retained binding 
to PGM, our carbohydrate ligand source for comparing antige-
nicity. Cluster I strains had less avidity for PGM than cluster II 
and IIIb VLPs, supporting previous observations with cluster I P 
particles [14]. It is unknown whether this difference could impact 
infection rates between GII.17 strains.
The emergence of GII.17 strains emphasizes the need for 
enhanced surveillance systems that include, at a minimum, 
complete P2 sequences and, ideally, the entire capsid and poly-
merase regions for virus typing. Only continued surveillance 
will answer the most important questions concerning GII.17 
strains: will GII.17 replace GII.4 as the leading cause of acute 
viral gastroenteritis? Will GII.17 cocirculate with GII.4, increas-
ing the global burden of norovirus disease or will GII.17 strains 
return to endemic levels of infection? Will the GII.4 continue 
to evolve by epochal evolution in human populations? From 3 
decades of GII.4 pandemics, we have learned that viruses with 
broad ligand binding patterns that undergo epochal evolution 
in response to herd immunity are a potential public health 
threat. As such, GII.17 should be considered as a component of 
a norovirus multivalent VLP vaccine or as a target of a cross-re-
active norovirus vaccine.
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